Merus to Present at the Canaccord Genuity 45th Annual Growth Conference
Rhea-AI Summary
Merus (NASDAQ: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. Bill Lundberg, M.D., the company's President and CEO, will engage in a fireside chat on Wednesday, August 13, 2025, at 1:30 p.m. ET.
The presentation will be available via webcast on the Investors section of Merus's website, with an archived version accessible for a limited time following the event.
Positive
- None.
Negative
- None.
News Market Reaction – MRUS
On the day this news was published, MRUS declined 2.83%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $137M from the company's valuation, bringing the market cap to $4.71B at that time.
Data tracked by StockTitan Argus on the day of publication.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, LinkedIn and Bluesky.
Multiclonics®, Biclonics®, Triclonics® and ADClonics® are registered trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl
Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
k.farren@merus.nl
FAQ
When is Merus (MRUS) presenting at the Canaccord Genuity Growth Conference 2025?
Who will represent Merus (MRUS) at the Canaccord Genuity Conference?
How can investors access Merus's (MRUS) presentation at the Canaccord Conference?
What type of company is Merus (MRUS)?
